u/mateusz_mensah

Has anyone posted an independent test on this compound recently?

What do you think the glucagon component is adding, specifically?

Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.

report the method or do not report the number

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

cycle timing changes how the same week feels

contraception absorption questions are real and they are worth asking about properly

Brought the cycle-annotated log to an appointment and it changed the conversation completely.

Disagree that this is a discrepancy.

Disagreeing with this line: that gap is ordinary variance, not a contradiction between the lab and the certificate.

Standing reminder: unapproved compound, research material is not for human use, and no schedules for other members.

trialwatch_theo is right that milligram comparisons across classes tell you nothing.

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

system suitability before you believe any number on the run

Agreed — logging the cycle alongside everything else is what made my own pattern visible. It was invisible before that.

What wavelength, and what was the gradient?

Yes — date of analysis, because a result from two years ago describes a different manufacturing month.

Not convinced by that integration. Dropping the baseline there absorbs part of the shoulder into the main peak.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Yes — nothing containing this is approved anywhere, and the threads keep forgetting it.

Agreed, and it is why the oral peptide comparison keeps misleading people.

The template is vendor, compound, batch, service, claim, result, and who paid. Every one of those fields exists because a result missing it has been argued about here before.

Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.

Same method at both labs, or two different gradients?

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that d

Agreed. And the corollary is that the method line on a certificate is not decoration, it is the number’s provenance.

Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.

area percent unless the report says otherwise

Kept every report as a PDF with the batch in the filename. Two years in, it is the most useful folder I own.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Is that the same lot as the one in the thread from last month?

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

Split one vial between Medutest and PeptideMeter. The two numbers were within half a point of each other and I stopped worrying about which lab to trust.

Correcting myself upthread: I said the gradient was linear and looking again it has a hold in the middle.

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.

Sent a vial to VendorInvestigate out of curiosity. Result was 98.6% against a claimed 98.5%, which is the first independent number I had seen for this compound anywhere.

wait for phase 3 before you argue about rankings

That is a phase 2 result being quoted as though the programme had reported.

the energy-expenditure story is mechanistically interesting and clinically unproven

Agreed, and it is why GL Biochem printing the column and gradient on the certificate is genuinely useful rather than decorative.

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

three lots beats three tests on one lot

Has this been raised with whoever prescribes?

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

Same. Perimenopause overlapping with all of this is the least documented area on the whole site.